OTCQB: VRTT: Groundbreaking technology focused on the treatment of patients with metastatic cancer.

 Fact Sheet  Research Report

Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The Company's lead product, the Viatar™ Therapeutic Oncopheresis System, removes circulating tumor cells (CTCs) from whole blood using label-free cross-flow filtration. It is designed to be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate, and gastric cancers. This proprietary technology also powers the Company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers, and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives. The Company’s liquid biopsy products are currently generating revenue, and sales are expected to increase in the coming quarters.

Find a broker to begin trading VRTT now

Investment HighlightsValue Proposition
Company Name Viatar CTC Solutions
Market/Symbol OTCQB: VRTT
Recent Price
Market Cap $19.50M
Avg. Daily Vol. (3m) 583
Price/Book N/A
Price/Cash Flow N/A
As of Oct. 21, 2016
*Source: QuoteMedia

Begin trading VRTT

 Find Broker

Recent Company Videos

Viatar: New Cancer Treatment Removes Tumor Cells from Blood

Oct. 29, 2015

Learn more at: http://www.redchip.com/company/healthcare/VRTT/279/medical-technology Viatar CTC Solutions Inc. (OTCQB: VRTT) is a medical technology ...

Investment Highlights

  • Addressable market is approximately 10 million cancer patients with Stage IV or metastatic disease
  • 90% of cancer deaths are due to metastatic disease

  • MIT study (2014) showed that interfering with CTCs stops the metastatic process
  • Georgia Tech study (2011) removed CTCs just once from mice with ovarian cancer; significantly slowed tumor progression (10.77x), and increased survival by 32%
  • University of Michigan study (2015) collected CTCs for 28 days from mice with breast cancer, leading to an 88% reduction of tumor cells in the lungs, 30% fewer metastatic lesions in the lungs, and 75% lower incidence of liver metastases.

  • Segment poised to grow as genetic testing becomes the standard of care

Near term commercialization opportunity for these products in Europe and Canada with CE Mark in late-2016

  • Projected gross and operating margins of 70% and 30%, respectively

Seasoned management team with impressive record growing medical technology companies

Value Proposition

VRTT has groundbreaking technology that is designed to be used in the large and under-served metastatic cancer market. The annual cost of care per cancer patient is $123,000, and Viatar’s system is targeted to cost only $15,000 annually while offering no side effects and improved survival rates as compared to chemotherapy. With approximately 10 million metastatic or stage IV cancer patients, penetrating only 1% of this market would lead to $1.5 billion in annual revenue. High margins ensure significant profit potential. VRTT CEO Ilan Reich has had substantial success in growing and operating medical device companies in the past; as Executive Vice President, President, and co-CEO of Inamed Corporation, he helped significantly improve the company’s performance and operations, which led to an acquisition by Allergan for $3.5 billion. Medical device companies with the CE Mark but no revenues are typically valued at $150-$250 million (or $8-$14 per VRTT share), and many early stage immunotherapy companies are valued at over $1 billion (or $50 per VRTT share). With strong animal data and potential CE Mark approval in late-2016, the stock presents a compelling entry point prior to results from the Company’s upcoming pilot study.

Viatar CTC Solutions Latest News

Latest Investor Presentation

Latest Investor Presentation

 View Full Presentation |  Download

Ask the CEO

VRTT Research

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

RedChip Direct Investment Opportunities For Private and Public Companies

Receive VRTT Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market